Diffuse Interstitial Lung Disease Linked to Vandetanib

Abstract

Vandetanib inhibits vascular endothelial growth factor receptor (VEGFR) 2 tyrosine kinase activity in endothelial cells and, to a lesser degree, endothelial growth factor receptor (EGFR) tyrosine kinase activity in tumor cells. Vandetanib has been developed for the treatment of non–small-cell lung cancer (NSCLC), either alone or in combination with second-line chemotherapy. We describe a case of interstitial lung disease (ILD) in a patient who received vandetanib in a randomized, controlled, double-blind trial by comparing a pemetrexed combination with either vandetanib or placebo.